Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Fasten Your Safety Belt Investors, There's Turbulence Ahead

Equities.com June 13, 2014

Biotech Investors Need to Focus on Catalysts

Equities.com June 11, 2014

Conatus (CNAT) Surges Amid Hepatitis C Fervor

Equities.com June 11, 2014

Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert

Marketwired June 11, 2014

Could Achillion (ACHN) be the Biggest Beneficiary of Merck's (MRK) Idenix (IDIX) Purchase?

Equities.com June 10, 2014

Achillion (ACHN) Soars After FDA OKs Resumption of Trial for Hepatitis C Drug

Equities.com June 10, 2014

Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10

Business Wire June 9, 2014

Merck (MRK) to pay triple last closing price for Idenix Pharmaceuticals (IDIX)

Canadian Press June 9, 2014

Catching Hepatitis: Why Merck (MRK) Was Willing to Break the Bank for Idenix (IDIX)

Equities.com June 9, 2014

Merck Beats Out AbbVie and JNJ, Agreeing to Pay $3.85 billion for Idenix

Equities.com June 9, 2014

Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia

Business Wire June 3, 2014

Quebec Becomes First Province to Reimburse Sovaldi® for the Treatment of Chronic Hepatitis C

Canada NewsWire June 2, 2014

Theralase Laser Technology Used By Star Athletes for Pain Management

Accesswire June 2, 2014

Gilead's Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults

Business Wire May 20, 2014

Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20

Business Wire May 19, 2014

Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14

Business Wire May 13, 2014

Gilead Announces Results from Phase 2 Study Showing Reduction in Atrial Fibrillation Burden with the Investigational Combination of Ranolazine and Low-Dose Dronedarone

Business Wire May 10, 2014

Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome

Business Wire May 9, 2014

Gilead Announces $5 Billion Share Repurchase Program

Business Wire May 7, 2014

Gilead Sciences Announces First Quarter 2014 Financial Results

Business Wire April 22, 2014